Opticyte has been capital-efficient and is funded for the next three years with a non-dilutive grant. The company has issued patents, a clear 510(k) pathway, and the potential to deliver significant cost savings to hospitals. Demonstrating strong momentum and credibility, Opticyte is a medical device innovator to watch.
The Opticyte Cell O₂ Monitor is a $3 Billion+ Global Market Opportunity
Connect with the Opticyte Team
If you’re a qualified investor and potential partner interested in Opticyte’s preclinical stage technology please reach out through our contact form.